Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Proteomics

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early and mature <i>Achromobacter xylosoxidans</i> biofilm in cystic fibrosis and non-cystic fibrosis isolates: dynamics and response to clinically relevant antibiotics.

Biofilm·2026

Same author

Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis.

Nature communications·2026

Same author

Specific and broad-spectrum antibacterial effectors of type VI secretion system drive competition of <i>Stenotrophomonas rhizophila</i> against bacteria from seed microbiota.

Microbiology spectrum·2026

Same author

ERO1a fosters glioblastoma aggressiveness and metabolic flexibility by regulating mitochondria-associated membrane dynamics.

Nature cell biology·2026

Same author

Dynamic proteomics of Nasonia vitripennis pupal development reveals testis-specific regulation of new proteins (orphans) likely related to exo-α-sialidases.

BMC genomics·2026

Same author

TSPO safeguards porphyrin-iron balance under anoxic conditions in <i>Bacillus cereus</i>.

mSystems·2026

Search research articles

Related Experiment Video

Updated: Oct 30, 2025

A Clinical Metaproteomics Workflow Implemented within Galaxy Bioinformatics Platform to Analyze Host-Microbiome Interactions Underlying Human Disease

A Clinical Metaproteomics Workflow Implemented within Galaxy Bioinformatics Platform to Analyze Host-Microbiome Interactions Underlying Human Disease

Published on: January 10, 2025

Metaproteomics to Decipher CF Host-Microbiota Interactions: Overview, Challenges and Future Perspectives.

Pauline Hardouin^1,2, Raphael Chiron³, Hélène Marchandin⁴

¹Laboratoire Innovations technologiques pour la Détection et le Diagnostic (Li2D), Université de Montpellier, 30207 Bagnols-sur-Cèze, France.

|July 2, 2021

Summary

Proteomics and metaproteomics offer new insights into the cystic fibrosis (CF) host-microbiota relationship. These methods help understand how microbial communities impact CF patient symptoms and treatment outcomes.

Keywords:

cystic fibrosis mass spectrometry microbiota proteomics

More Related Videos

Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples

Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples

Published on: December 22, 2014

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Oct 30, 2025

A Clinical Metaproteomics Workflow Implemented within Galaxy Bioinformatics Platform to Analyze Host-Microbiome Interactions Underlying Human Disease

A Clinical Metaproteomics Workflow Implemented within Galaxy Bioinformatics Platform to Analyze Host-Microbiome Interactions Underlying Human Disease

Published on: January 10, 2025

Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples

Purifying the Impure: Sequencing Metagenomes and Metatranscriptomes from Complex Animal-associated Samples

Published on: December 22, 2014

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Area of Science:

Microbiology
Genetics
Biochemistry

Background:

Cystic fibrosis (CF) is a genetic disorder caused by CF transmembrane conductance regulator (CFTR) gene mutations, leading to organ dysfunction and chronic infections.
The gut and lung microbiota play a significant role in CF pathogenesis, influencing disease severity, treatment response, and overall patient phenotype.

Purpose of the Study:

To review the application of proteomics and metaproteomics in understanding the CF host-microbiota interactions.
To highlight the potential of these omics tools in unraveling the complexities of CF-associated microbial communities.

Main Methods:

Proteomics and metaproteomics approaches are utilized to analyze microbial communities and host responses in CF patients.
The review discusses the strengths and limitations of these techniques in profiling respiratory and intestinal microbiota.

Main Results:

Proteomics provides insights into the key effectors of host-microbe interactions, revealing their role in CF phenotypes.
Recent advances in omics tools are enhancing our understanding of the CF microbiota and its impact on disease progression.

Conclusions:

Proteomics and metaproteomics are valuable tools for studying the CF host-microbiota partnership.
Further development of these approaches is needed to overcome limitations in monitoring CF-associated microbial communities in both respiratory and intestinal samples.